It is well known that inflammatory mechanisms play a crucial role in the pathogenesis of atherosclerosis and coronary artery disease. In recent years, allergic episodes have been shown to be associated with acute coronary syndromes. Mast cells release certain inflammatory mediators including histamine and neutral proteases during an allergic episode and these inflammatory mediators are implied to induce coronary artery spasm and/or atheromatous plaque erosion or rupture. As the inflammatory component of acute coronary syndromes is a potential therapeutic target, drugs that stabilize mast cell membrane and monoclonal antibodies that protect mast cell surface may be effective in preventing allergy associated acute coronary syndromes. In this review, we will mention the role of inflammation and allergy and antiinflammatory therapeutic modalities in acute coronary syndromes.
Inflammation & Allergy - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in inflammation and allergy e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in inflammation and allergy. As the discovery, identification, characterization and validation of novel human drug targets for anti-inflammation and allergy drug discovery continues to grow, this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.